Maze Therapeutics, Inc.
MAZE
$27.18
-$0.49-1.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 20.00M | 20.00M | -- | 0.00 | 2.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.00M | 20.00M | -- | 0.00 | 2.50M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 20.00M | 20.00M | -- | 0.00 | 2.50M |
| SG&A Expenses | 43.76M | 39.04M | 34.45M | 31.47M | 30.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 165.61M | 154.05M | 142.90M | 134.57M | 128.33M |
| Operating Income | -145.61M | -134.05M | -142.90M | -134.57M | -125.83M |
| Income Before Tax | -133.59M | -122.54M | -131.12M | -126.41M | -121.35M |
| Income Tax Expenses | -- | -- | -- | -275.00K | -554.00K |
| Earnings from Continuing Operations | -133.59 | -122.54 | -131.12 | -126.13 | -120.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -133.59M | -122.54M | -131.12M | -126.13M | -120.80M |
| EBIT | -145.61M | -134.05M | -142.90M | -134.57M | -125.83M |
| EBITDA | -143.71M | -131.89M | -140.50M | -131.96M | -123.00M |
| EPS Basic | -2.51 | -2.52 | -3.22 | -4.59 | -14.18 |
| Normalized Basic EPS | -1.57 | -1.58 | -2.01 | -8.86 | -14.24 |
| EPS Diluted | -2.52 | -2.53 | -3.22 | -4.89 | -14.48 |
| Normalized Diluted EPS | -1.57 | -1.58 | -2.01 | -8.86 | -14.24 |
| Average Basic Shares Outstanding | 212.07M | 196.87M | 171.60M | 120.64M | 77.27M |
| Average Diluted Shares Outstanding | 212.07M | 196.87M | 171.60M | 120.64M | 77.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |